Initiating therapy: when to start, what to use.

Area of Science:

• Infectious Diseases
• Virology
• Immunology

Background:

• Treatment guidelines for Human Immunodeficiency Virus (HIV) infection are continuously updated.
• The optimal timing for initiating combination antiretroviral therapy (cART) remains a key area of research.

Purpose of the Study:

• To review current evidence on the benefits and timing of cART initiation in HIV infection.
• To discuss evolving recommendations for cART initiation and maintenance.

Main Methods:

• Literature review of recent studies on cART initiation and maintenance in HIV.
• Analysis of data regarding CD4 cell count thresholds for treatment initiation.
• Evaluation of different cART regimens and emerging drug classes.

Main Results:

• Evidence suggests potential benefits of cART during primary HIV infection, but data are not conclusive.
• Stopping cART after initiation may diminish its long-term advantages.
• Current guidelines may recommend initiating cART at higher CD4 cell counts than previously advised.

Conclusions:

• The decision to initiate cART during primary HIV infection requires further investigation.
• Continuous cART is likely necessary to maintain therapeutic benefits.
• Newer antiretroviral agents, including integrase inhibitors, show promise for treatment-naive individuals.